Lilly has lost the latest round in an enduring legal fight over patents casing the administration of vitamins in conjunction with its epic lung cancer drug, Alimta (pemexetred). According to UK High Court, Lilly’s Alimta vitamin regimen patent would not be infringed by Allergan marketing its drug in the UK, France, Italy and Spain with instructions to dilute the product only with dextrose solution. [more]
top of page
Search
Recent Posts
See AllGeneral Motors has secured an Indian patent on a hybrid powertrain control system for vehicles. The patent rights are currently assigned...
Taking into consideration the Delhi High court’s order staying the abandonment orders passed by the Trademarks Office, the Registrar of...
The order of the Delhi High Court allows the Competition Commission of India (CCI) to attend to complaints on abuse of dominance of...
bottom of page
Comentarios